ATE419002T1 - Behandlung von nierenzellen-karzinom - Google Patents

Behandlung von nierenzellen-karzinom

Info

Publication number
ATE419002T1
ATE419002T1 AT05002952T AT05002952T ATE419002T1 AT E419002 T1 ATE419002 T1 AT E419002T1 AT 05002952 T AT05002952 T AT 05002952T AT 05002952 T AT05002952 T AT 05002952T AT E419002 T1 ATE419002 T1 AT E419002T1
Authority
AT
Austria
Prior art keywords
treatment
cell carcinoma
renal cell
renal
carcinoma
Prior art date
Application number
AT05002952T
Other languages
English (en)
Inventor
Esther Helen Rose
Mary Ellen Rybak
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE419002T1 publication Critical patent/ATE419002T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AT05002952T 1999-04-08 2000-04-06 Behandlung von nierenzellen-karzinom ATE419002T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28835999A 1999-04-08 1999-04-08

Publications (1)

Publication Number Publication Date
ATE419002T1 true ATE419002T1 (de) 2009-01-15

Family

ID=23106761

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00107100T ATE296638T1 (de) 1999-04-08 2000-04-06 Behandlung von nierenzellen-karzinom
AT05002952T ATE419002T1 (de) 1999-04-08 2000-04-06 Behandlung von nierenzellen-karzinom

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT00107100T ATE296638T1 (de) 1999-04-08 2000-04-06 Behandlung von nierenzellen-karzinom

Country Status (24)

Country Link
EP (2) EP1043025B1 (de)
JP (2) JP4721488B2 (de)
CN (1) CN1367702A (de)
AR (1) AR029160A1 (de)
AT (2) ATE296638T1 (de)
AU (2) AU777406B2 (de)
BR (1) BR0009644A (de)
CA (1) CA2303752A1 (de)
CO (1) CO5170412A1 (de)
CY (1) CY1108919T1 (de)
DE (2) DE60041291D1 (de)
DK (2) DK1043025T3 (de)
ES (2) ES2239953T3 (de)
HK (2) HK1032533A1 (de)
HU (1) HU230271B1 (de)
MX (1) MXPA00003401A (de)
MY (1) MY155221A (de)
NO (1) NO328983B1 (de)
NZ (1) NZ514629A (de)
PE (1) PE20010026A1 (de)
PT (2) PT1043025E (de)
TW (2) TWI310314B (de)
WO (1) WO2000061174A2 (de)
ZA (1) ZA200108169B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1043025E (pt) * 1999-04-08 2005-09-30 Schering Corp Tratamento de carcinoma da celula renal
US20070231301A1 (en) * 2006-03-31 2007-10-04 Warren Stephen L Parenteral low dose type 1 interferons for bladder cancer
TW200901989A (en) * 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
US8053430B2 (en) 2008-10-06 2011-11-08 Haraldsson Boerje Treatment of renal cell carcinoma
WO2011123027A1 (en) 2010-04-01 2011-10-06 Haraldsson Boerje Improved treatment of renal cell carcinoma
CN103463623B (zh) * 2013-09-03 2015-09-09 长春海伯尔生物技术有限责任公司 一种聚乙二醇干扰素注射液及其制备方法
EP3630813A1 (de) 2017-05-24 2020-04-08 Novartis AG Antikörper-zytokin- gepfropfte proteine und verfahren zur verwendung in der krebsbehandlung

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766582A (en) * 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
HU228877B1 (en) * 1998-03-26 2013-06-28 Merck Sharp & Dohme Formulations for stabilization of peg-interferon alpha conjugates and method for preparation such formulations
PT1043025E (pt) * 1999-04-08 2005-09-30 Schering Corp Tratamento de carcinoma da celula renal

Also Published As

Publication number Publication date
JP2001288110A (ja) 2001-10-16
CO5170412A1 (es) 2002-06-27
HUP0200781A3 (en) 2002-09-30
NZ514629A (en) 2004-02-27
DE60041291D1 (de) 2009-02-12
MXPA00003401A (es) 2002-03-08
PT1043025E (pt) 2005-09-30
HU230271B1 (hu) 2015-11-30
EP1043025B1 (de) 2005-06-01
AU4204400A (en) 2000-11-14
JP3712914B2 (ja) 2005-11-02
AU2004242454A1 (en) 2005-01-20
DK1043025T3 (da) 2005-07-04
PE20010026A1 (es) 2001-02-05
WO2000061174A2 (en) 2000-10-19
EP1535623B1 (de) 2008-12-31
ES2319777T3 (es) 2009-05-12
JP2000319196A (ja) 2000-11-21
MY155221A (en) 2015-09-30
CY1108919T1 (el) 2014-07-02
WO2000061174A3 (en) 2001-01-25
HUP0200781A2 (en) 2002-08-28
DK1535623T3 (da) 2009-04-27
ATE296638T1 (de) 2005-06-15
AU2004242454B2 (en) 2007-02-15
DE60020442T2 (de) 2006-05-04
EP1043025A3 (de) 2000-12-20
JP4721488B2 (ja) 2011-07-13
ES2239953T3 (es) 2005-10-16
NO20014851L (no) 2001-12-07
TW200526243A (en) 2005-08-16
DE60020442D1 (de) 2005-07-07
CA2303752A1 (en) 2000-10-08
CN1367702A (zh) 2002-09-04
TWI310314B (en) 2009-06-01
AR029160A1 (es) 2003-06-18
ZA200108169B (en) 2003-01-06
AU777406B2 (en) 2004-10-14
EP1043025A2 (de) 2000-10-11
NO20014851D0 (no) 2001-10-05
HK1032533A1 (en) 2001-07-27
BR0009644A (pt) 2002-01-08
HK1075417A1 (en) 2005-12-16
NO328983B1 (no) 2010-07-05
EP1535623A1 (de) 2005-06-01
PT1535623E (pt) 2009-03-19

Similar Documents

Publication Publication Date Title
DE69925306D1 (de) Behandlung von kohlenwasserstoffgas
DE60001421D1 (de) Behandlung von abgas
ATE260332T1 (de) Behandlung von textilien
ATE300597T1 (de) Behandlung von geweben
ATE301617T1 (de) Behandlung von wasser
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE69939575D1 (de) Entdeckung von Diensten in unmittelbarer Nähe
DE69836735D1 (de) Behandlung von darmverstopfung
ATE298241T1 (de) Behandlung von atemstillstand im schlaf
DE69817446D1 (de) Behandlung von diabetes
FI20000863A (fi) Uusi hoitomenetelmä
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60040607D1 (de) Wasserbehandlungseinrichtung
DE60118179D1 (de) Behandlung von zirkulierenden wassersystemen
DE69918171D1 (de) Wäschebehandlung
DE60021065D1 (de) Virus behandlung
NO20013337D0 (no) Ny behandling
DE69932235D1 (de) Behandlung von herzhypertrophie
DE60020442D1 (de) Behandlung von Nierenzellen-Karzinom
DE60026821D1 (de) Behandlung von bohrspülung
ATE302165T1 (de) Wasserbehandlung
ATE290060T1 (de) Wäschebehandlung
DE69904762D1 (de) Behandlung von flachs-saatgut
DE60011060D1 (de) Virus behandlung
DE60103071D1 (de) Behandlung von flüssigkeiten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1535623

Country of ref document: EP